Cardiac Arrest Treatment Market To Reach $23.0 billion by 2035

Cardiac arrest treatment market was valued at $13.5 billion in 2025 and is projected to reach $23.0 billion by 2035, expanding at a CAGR of 5.8% during the forecast period. Market growth is primarily driven by the rising incidence of sudden cardiac arrest and increasing deployment of emergency response infrastructure. According to the World Health Organization, cardiovascular diseases account for nearly 17.9 million deaths annually, with a significant portion linked to sudden cardiac arrest. This growing burden is increasing demand for defibrillators, emergency drugs, and ICU-based post-arrest care. Additionally, the expansion of emergency medical services (EMS) and public access defibrillation programs is strengthening treatment accessibility across both developed and emerging regions.

Browse the full report description of “Cardiac Arrest Treatment Market Size, Share & Trends Analysis Report By Product Type (External Defibrillators, Implantable Devices, Emergency Drugs, Monitoring Systems), By Treatment Type (Pharmacological Treatment, Device-Based Treatment, Post-Cardiac Arrest Care), By Application (Out-of-Hospital Cardiac Arrest (OHCA), In-Hospital Cardiac Arrest (IHCA)), By End-Use Industry (Hospitals & Cardiac Centers, Emergency Medical Services (EMS), Public Access Settings, Home Care Settings), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/cardiac-arrest-treatment-market-outlook

key Leaders Transforming the Cardiac Arrest Treatment Market

The key players in the cardiac arrest treatment market include top companies such as Pfizer Inc., Abbott Laboratories, Medtronic plc, Stryker Corporation, and GE HealthCare Technologies Inc., among others. The market is witnessing steady growth driven by increasing adoption of automated external defibrillators (AEDs) in public settings and advancements in implantable cardiac devices. Hospitals and EMS providers are expanding their emergency care capabilities to improve survival rates from out-of-hospital cardiac arrest (OHCA). Additionally, technological advancements in monitoring systems and targeted temperature management are enhancing post-cardiac arrest outcomes.

• In August 2025, Koninklijke Philips N.V. showcased AI-driven cardiac care solutions at the European Society of Cardiology (ESC) Congress 2025, focusing on advanced imaging, real-time monitoring, and workflow optimization. These technologies enable faster diagnosis, more precise treatment planning, and proactive patient management across the cardiac care continuum. The company highlighted integrated AI-enabled systems that improve clinical efficiency and decision-making in cardiology.

• In June 2025, GE HealthCare Technologies Inc. showcased advanced molecular imaging solutions, including PET/CT and SPECT/CT systems, to enhance cardiac diagnostics at the SNMMI annual meeting. These technologies enable early detection of cardiovascular conditions and precise assessment of myocardial function, supporting improved clinical decision-making. The solutions help tailor treatment strategies and monitor disease progression, contributing to better patient outcomes. While primarily diagnostic, these innovations indirectly support the cardiac arrest treatment ecosystem by improving early intervention and post-event management.

• In June 2024, Stryker Corporation announced the launch of its LIFEPAK 35 monitor/defibrillator, a next-generation device designed for emergency responders and hospital settings. The system integrates advanced monitoring and defibrillation capabilities with real-time patient data access to support critical decision-making during cardiac emergencies. It is built on a modern, intuitive platform aimed at improving workflow efficiency and reducing caregiver burden. This innovation strengthens Stryker’s position in the cardiac arrest treatment market by enhancing emergency response and patient care outcomes.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-
• By Product Type
• By Treatment Type
• By Application
• By End-User
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape: Pfizer Inc., Abbott Laboratories, Medtronic plc, Stryker Corporation, and GE HealthCare Technologies Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cardiac Arrest Treatment Market Report Segment

By Product Type

• External Defibrillators
• Implantable Devices
• Emergency Drugs
• Monitoring Systems

By Treatment Type

• Pharmacological Treatment
• Device-Based Treatment
• Post-Cardiac Arrest Care

By Application

• Out-of-Hospital Cardiac Arrest (OHCA)
• In-Hospital Cardiac Arrest (IHCA)

By End-User

• Hospitals & Cardiac Centers
• Emergency Medical Services (EMS)
• Public Access Settings
• Home Care Settings

Global Cardiac Arrest Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cardiac-arrest-treatment-market-outlook